Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Polymer adhesion predictions for oral dosage forms to enhance drug administration safety. Part 2: In vitro approach using mechanical force methods.

Drumond N, Stegemann S.

Colloids Surf B Biointerfaces. 2018 Mar 5;166:17-23. doi: 10.1016/j.colsurfb.2018.03.006. [Epub ahead of print]

PMID:
29525622
2.

Polymer adhesion predictions for oral dosage forms to enhance drug administration safety. Part 3: Review of in vitro and in vivo methods used to predict esophageal adhesion and transit time.

Drumond N, Stegemann S.

Colloids Surf B Biointerfaces. 2018 May 1;165:303-314. doi: 10.1016/j.colsurfb.2018.02.050. Epub 2018 Feb 24. Review.

PMID:
29524806
3.

Polymer adhesion predictions for oral dosage forms to enhance drug administration safety. Part 1: In vitro approach using particle interaction methods.

Drumond N, Stegemann S.

Colloids Surf B Biointerfaces. 2018 May 1;165:9-17. doi: 10.1016/j.colsurfb.2018.02.012. Epub 2018 Feb 9.

PMID:
29448218
4.

Improving Therapeutics to Better Care for Older Adults and the Young: Report From the American College of Clinical Pharmacology Workshop.

Lau SWJ, Schlender JF, Abernethy DR, Burckart GJ, Golden A, Slattum PW, Stegemann S, Eissing T.

J Clin Pharmacol. 2017 Oct 11. doi: 10.1002/jcph.1024. [Epub ahead of print] No abstract available.

PMID:
29023776
5.

Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids.

Suys EJA, Warren DB, Porter CJH, Benameur H, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Nov 6;14(11):3684-3697. doi: 10.1021/acs.molpharmaceut.7b00446. Epub 2017 Oct 5.

PMID:
28980815
6.

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.

Sahbaz Y, Nguyen TH, Ford L, McEvoy CL, Williams HD, Scammells PJ, Porter CJH.

Mol Pharm. 2017 Nov 6;14(11):3669-3683. doi: 10.1021/acs.molpharmaceut.7b00442. Epub 2017 Oct 10.

PMID:
28954512
7.

A system identification approach for developing model predictive controllers of antibody quality attributes in cell culture processes.

Downey B, Schmitt J, Beller J, Russell B, Quach A, Hermann E, Lyon D, Breit J.

Biotechnol Prog. 2017 Nov;33(6):1647-1661. doi: 10.1002/btpr.2537. Epub 2017 Aug 24.

8.

Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans.

Murray K, Hoad CL, Mudie DM, Wright J, Heissam K, Abrehart N, Pritchard SE, Al Atwah S, Gowland PA, Garnett MC, Amidon GE, Spiller RC, Amidon GL, Marciani L.

Mol Pharm. 2017 Aug 7;14(8):2629-2638. doi: 10.1021/acs.molpharmaceut.7b00095. Epub 2017 Jul 6.

9.

Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in Rats.

Stewart AM, Grass ME, Brodeur TJ, Goodwin AK, Morgen MM, Friesen DT, Vodak DT.

Mol Pharm. 2017 Jul 3;14(7):2437-2449. doi: 10.1021/acs.molpharmaceut.7b00338. Epub 2017 Jun 22.

10.

Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.

Williams HD, Ford L, Lim S, Han S, Baumann J, Sullivan H, Vodak D, Igonin A, Benameur H, Pouton CW, Scammells PJ, Porter CJH.

J Pharm Sci. 2018 Jan;107(1):203-216. doi: 10.1016/j.xphs.2017.05.019. Epub 2017 May 23.

PMID:
28549907
11.

Development of a Biorelevant, Material-Sparing Membrane Flux Test for Rapid Screening of Bioavailability-Enhancing Drug Product Formulations.

Stewart AM, Grass ME, Mudie DM, Morgen MM, Friesen DT, Vodak DT.

Mol Pharm. 2017 Jun 5;14(6):2032-2046. doi: 10.1021/acs.molpharmaceut.7b00121. Epub 2017 May 10.

12.

Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery.

Morgen M, Saxena A, Chen XQ, Miller W, Nkansah R, Goodwin A, Cape J, Haskell R, Su C, Gudmundsson O, Hageman M, Kumar A, Chowan GS, Rao A, Holenarsipur VK.

Eur J Pharm Biopharm. 2017 Aug;117:212-223. doi: 10.1016/j.ejpb.2017.04.021. Epub 2017 Apr 21.

13.

Patients' appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence.

Drumond N, van Riet-Nales DA, Karapinar-Çarkit F, Stegemann S.

Int J Pharm. 2017 Apr 15;521(1-2):294-305. doi: 10.1016/j.ijpharm.2017.02.029. Epub 2017 Feb 14. Review.

PMID:
28229945
14.

Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.

Jones RM, Burke M, Dubose D, Chichester JA, Manceva S, Horsey A, Streatfield SJ, Breit J, Yusibov V.

Vaccine. 2017 Oct 4;35(41):5463-5470. doi: 10.1016/j.vaccine.2016.12.009. Epub 2017 Jan 20.

PMID:
28117174
15.

Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids.

Birru WA, Warren DB, Headey SJ, Benameur H, Porter CJ, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Mar 6;14(3):566-579. doi: 10.1021/acs.molpharmaceut.6b00888. Epub 2017 Feb 15.

PMID:
28099023
16.

Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.

Birru WA, Warren DB, Han S, Benameur H, Porter CJ, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Mar 6;14(3):580-592. doi: 10.1021/acs.molpharmaceut.6b00887. Epub 2017 Feb 15.

PMID:
27936778
17.

Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application.

Jain S, Patel N, Shah MK, Khatri P, Vora N.

J Pharm Sci. 2017 Feb;106(2):423-445. doi: 10.1016/j.xphs.2016.10.001. Epub 2016 Nov 16. Review.

PMID:
27865609
18.

The gut in the beaker: Missing the surfactants?

Wilson CG, Halbert GW, Mains J.

Int J Pharm. 2016 Oct 15. pii: S0378-5173(16)30853-5. doi: 10.1016/j.ijpharm.2016.09.032. [Epub ahead of print] Review.

PMID:
27863989
19.

The gut in the beaker: Missing the surfactants?

Wilson CG, Halbert GW, Mains J.

Int J Pharm. 2016 Nov 30;514(1):73-80. doi: 10.1016/j.ijpharm.2016.09.032. Review.

PMID:
27863685
20.

Defining Patient Centric Pharmaceutical Drug Product Design.

Stegemann S, Ternik RL, Onder G, Khan MA, van Riet-Nales DA.

AAPS J. 2016 Sep;18(5):1047-55. doi: 10.1208/s12248-016-9938-6. Epub 2016 Jun 17. Review.

PMID:
27317470

Supplemental Content

Loading ...
Support Center